Fuzeon makers launch 60-day free access program
Roche and Trimeris, the makers of the HIV fusion inhibitor Fuzeon, this month launched the Fuzeon Accelerated Simultaneous Access Program (Fuzeon ASAP), which provides immediate access to up to a 60-day free supply of the drug to HIV patients also taking an experimental anti-HIV drug through an expanded access program. Fuzeon, an injectable medication, is the only anti-HIV medication available in the fusion inhibitor class. It works by preventing HIV from attaching to and infecting immune system cells.
Roche and Trimeris, in a letter sent to the nation's HIV caregivers, announced the new program, which provides HIV patients starting Fuzeon treatment in combination with an investigational medication up to 60 days' worth of Fuzeon, with the first 30-day supply shipped immediately; reimbursement assistance services to guarantee ongoing access to Fuzeon, including through Roche's patient assistance program; support services as needed, including home nurse visits for injection training; and adherence programs as needed. Doctors wishing to enroll patients in Fuzeon ASAP and HIV patients with questions about the program should call the Fuzeon Answer Center at (877) 438-9366.